Please assess the completion status of the following clinical trial:

Trial Title: Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any woman with prior SCAD who is at least 3 months out from her SCAD and has ongoing symptoms of chest pain.~* Females of child-bearing age must have a negative pregnancy test at enrollment~* Coronary Flow Reserve(CFR) \< 3.0~Exclusion Criteria:~* Renal dysfunction with Glomerular Filtration Rate \<50 ml/min~* Patients not willing to undergo coronary angiography~* Patients with a prior intolerance or allergy to rosuvastatin or ramipril~* Inability to perform CRT or CFR \>3.0~* Obstructive coronary artery disease (stenosis \>50% in any artery) or residual dissection \>50% with distal flow abnormalities

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin, placebo (Type: EXPERIMENTAL): rosuvastatin 10-20mg daily or placebo (suggested dose of 10mg for Asians, and 20mg for others)
- Ramipril, placebo (Type: EXPERIMENTAL): ramipril (starting dose of ramipril at 5mg daily titrating up to 10mg daily at 1 week if tolerated) versus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).